deltatrials

Chronic myeloid leukemia Trials in Paris, France

Conditions / Chronic myeloid leukemia / Paris, France

Research into Chronic myeloid leukemia spans multiple therapeutic approaches and trial phases.

18 total trials for this combination

Showing top 10 of 18 trials

Trials

NCT ID Title Status Phase
NCT06163430 A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL) RECRUITING PHASE1/PHASE2
NCT01207440 Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL) COMPLETED PHASE2
NCT00101660 Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib COMPLETED PHASE2
NCT00101595 Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia COMPLETED PHASE2
NCT00103844 Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia COMPLETED PHASE2
NCT01650805 Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC) TERMINATED PHASE3
NCT00101816 Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate COMPLETED PHASE2
NCT00462943 Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML COMPLETED PHASE2
NCT00375219 Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation COMPLETED PHASE2
NCT00302016 Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia NO_LONGER_AVAILABLE

Related Pages